Shares of clinical-stage biopharmaceutical company Immunic (NASDAQ:IMUX) are soaring higher today after the company announced promising data from a Phase 2 study evaluating vidofludimus calcium (IMU-838) for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Long-term treatment with Immunic’s lead candidate was associated with a low rate of disability worsening over time. Further, the results compare favorably with available trial data for current MS medications.
Despite today’s price gains, Immunic shares are still down ~87% year-to-date. Moreover, short interest in the stock remains elevated at about 23.6% at present.
Read full Disclosure